ATE296881T1 - Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff - Google Patents

Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff

Info

Publication number
ATE296881T1
ATE296881T1 AT99911949T AT99911949T ATE296881T1 AT E296881 T1 ATE296881 T1 AT E296881T1 AT 99911949 T AT99911949 T AT 99911949T AT 99911949 T AT99911949 T AT 99911949T AT E296881 T1 ATE296881 T1 AT E296881T1
Authority
AT
Austria
Prior art keywords
vaccine
ompf
aroc
usable
reverting mutation
Prior art date
Application number
AT99911949T
Other languages
English (en)
Inventor
Steven Neville Chatfield
Original Assignee
Acambis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Res Ltd filed Critical Acambis Res Ltd
Application granted granted Critical
Publication of ATE296881T1 publication Critical patent/ATE296881T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0258Escherichia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C12N15/03Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575Hormones
    • G01N2333/65Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
AT99911949T 1998-03-25 1999-03-25 Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff ATE296881T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9806449.6A GB9806449D0 (en) 1998-03-25 1998-03-25 Attenuated bacteria useful in vaccines
PCT/GB1999/000935 WO1999049026A1 (en) 1998-03-25 1999-03-25 Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines

Publications (1)

Publication Number Publication Date
ATE296881T1 true ATE296881T1 (de) 2005-06-15

Family

ID=10829280

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99911949T ATE296881T1 (de) 1998-03-25 1999-03-25 Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff

Country Status (19)

Country Link
US (1) US6902906B1 (de)
EP (1) EP1066376B1 (de)
JP (1) JP4516210B2 (de)
KR (1) KR100628657B1 (de)
AT (1) ATE296881T1 (de)
AU (1) AU763683B2 (de)
CA (1) CA2323576C (de)
CZ (1) CZ301520B6 (de)
DE (1) DE69925585T2 (de)
DK (1) DK1066376T3 (de)
ES (1) ES2244182T3 (de)
GB (1) GB9806449D0 (de)
HU (1) HU225644B1 (de)
NO (1) NO327609B1 (de)
NZ (1) NZ507077A (de)
PL (1) PL196076B1 (de)
PT (1) PT1066376E (de)
WO (1) WO1999049026A1 (de)
ZA (1) ZA200004987B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
DE60213948T2 (de) * 2001-01-18 2007-03-08 Newcastle University Ventures Ltd. Biosensor mit kovalent gebundenen membranüberspannenden proteinen
GB0121998D0 (en) 2001-09-11 2001-10-31 Acambis Res Ltd Attenuated bacteria useful in vaccines
US7357935B2 (en) * 2003-05-14 2008-04-15 Wyeth Avian E. coli vaccine for protection against colibacillosis
US7297338B2 (en) * 2003-05-14 2007-11-20 Wyeth Avian vaccine composition for the protection of poultry against disease and infection caused by E. coli and Salmonella
EP1981536A4 (de) * 2006-02-01 2012-03-14 Gotovax Ab Kolonisationsfaktorantigene enterotoxigener escherichia coli in rekombinanten bakterien
JP2008054614A (ja) * 2006-09-01 2008-03-13 Nippon Inst For Biological Science 鶏大腸菌由来弱毒変異株、鶏大腸菌対策用ワクチン、免疫方法及び鶏用ワクチンベクター
EP2517723B1 (de) * 2006-09-18 2019-11-06 The Board of Trustees of The University of Arkansas Zusammensetzungen und Verfahren zur Verstärkung von Immunreaktionen
CA2704457A1 (en) * 2007-10-30 2009-05-07 Walter Bottje Compositions and methods of enhancing immune responses to flagellated bacterium
NZ585777A (en) 2007-11-01 2012-09-28 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria
NZ601609A (en) 2010-01-21 2014-08-29 Univ Arkansas Vaccine vectors and methods of enhancing immune responses
AU2011264772B2 (en) 2010-06-09 2015-07-16 The Board Of Trustees Of The University Of Arkansas Vaccine and methods to reduce Campylobacter infection
WO2014037445A1 (en) * 2012-09-05 2014-03-13 Lohmann Animal Health Gmbh Preparation of live vaccines
AU2013311675A1 (en) * 2012-12-07 2015-05-21 Lohmann Animal Health Gmbh Preparation of live vaccines
US9603915B2 (en) 2013-02-14 2017-03-28 The Board of Trustees of the University of Akansas Compositions and methods of enhancing immune responses to Eimeria or limiting Eimeria infection
KR102239207B1 (ko) 2013-03-15 2021-04-09 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 장내 병원균에 대한 면역 반응을 증진시키는 조성물 및 방법
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8730037D0 (en) 1987-12-23 1988-02-03 Wellcome Found Vaccines
GB8912330D0 (en) 1989-05-30 1989-07-12 Wellcome Found Live vaccines
DE69012784D1 (de) 1990-02-06 1994-10-27 Pasteur Institut Transformiertes Shigella.
GB9007194D0 (en) 1990-03-30 1990-05-30 Wellcome Found Live vaccines
EP0574466B1 (de) * 1991-03-05 1999-05-19 The Wellcome Foundation Limited Expression rekombinanter proteine in attenuierten bakterien

Also Published As

Publication number Publication date
US6902906B1 (en) 2005-06-07
CZ301520B6 (cs) 2010-03-31
NO327609B1 (no) 2009-08-31
AU3045899A (en) 1999-10-18
ZA200004987B (en) 2001-10-31
DE69925585D1 (de) 2005-07-07
ES2244182T3 (es) 2005-12-01
CZ20003470A3 (cs) 2001-07-11
JP2002507414A (ja) 2002-03-12
CA2323576A1 (en) 1999-09-30
PT1066376E (pt) 2005-10-31
EP1066376A1 (de) 2001-01-10
HU225644B1 (en) 2007-05-02
PL343246A1 (en) 2001-07-30
CA2323576C (en) 2010-12-07
GB9806449D0 (en) 1998-05-27
HUP0105430A2 (hu) 2002-04-29
KR100628657B1 (ko) 2006-09-26
KR20010042175A (ko) 2001-05-25
JP4516210B2 (ja) 2010-08-04
EP1066376B1 (de) 2005-06-01
WO1999049026A1 (en) 1999-09-30
PL196076B1 (pl) 2007-12-31
NO20004781D0 (no) 2000-09-25
HUP0105430A3 (en) 2004-10-28
NZ507077A (en) 2002-10-25
DE69925585T2 (de) 2006-07-13
DK1066376T3 (da) 2005-10-03
NO20004781L (no) 2000-11-08
AU763683B2 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
ATE296881T1 (de) Bakterien abgeschwächt durch einen nicht revertierende mutation in jeden der aroc, ompf und ompc gene, verwendbar als impstoff
Jutras et al. Borrelia burgdorferi peptidoglycan is a persistent antigen in patients with Lyme arthritis
Oyston et al. The response regulator PhoP is important for survival under conditions of macrophage-induced stress and virulence in Yersinia pestis
Balsanelli et al. Herbaspirillum seropedicae rfbB and rfbC genes are required for maize colonization
Abd et al. Intracellular survival and replication of Vibrio cholerae O139 in aquatic free‐living amoebae
Kristich et al. Esp-independent biofilm formation by Enterococcus faecalis
Rashid et al. Identification of genes involved in the switch between the smooth and rugose phenotypes of Vibrio cholerae
Beenken et al. Mutation of sarA in Staphylococcus aureus limits biofilm formation
Claeys et al. The many lives of nontuberculous mycobacteria
Adékambi et al. Survival of environmental mycobacteria in Acanthamoeba polyphaga
Ngampasutadol et al. Human C4b-binding protein selectively interacts with Neisseria gonorrhoeae and results in species-specific infection
Weissman et al. Clonal analysis reveals high rate of structural mutations in fimbrial adhesins of extraintestinal pathogenic Escherichia coli
Taylor et al. Oral immunization with a dam mutant of Yersinia pseudotuberculosis protects against plague
Poly et al. Genome sequence of a clinical isolate of Campylobacter jejuni from Thailand
Yu et al. Characterization of the Streptococcus pneumoniae NADH oxidase that is required for infection
Hayashi et al. The autolysin of Porphyromonas gingivalis is involved in outer membrane vesicle release
EP0717777A4 (de) Salmonella impfstoffe
GB0424092D0 (en) Immunogenic bacterial vesicles with outer membrane proteins
Oelschlaeger et al. The high-pathogenicity island is absent in human pathogens of Salmonella enterica subspecies I but present in isolates of subspecies III and VI
Hilali et al. Prevalence of virulence genes and clonality in Escherichia coli strains that cause bacteremia in cancer patients
Zogaj et al. Characterization of the Francisella tularensis subsp. novicida type IV pilus
ATE173166T1 (de) Neue bakterielle impfstoffe unter verwendung von impfstämmen von pathogenen bakterien
Freire et al. Serine protease autotransporters of Enterobacteriaceae (SPATEs) are largely distributed among Escherichia coli isolated from the bloodstream
Salaun et al. Phase variation mediated niche adaptation during prolonged experimental murine infection with Helicobacter pylori
DE60207277D1 (de) Bakterieller impfstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1066376

Country of ref document: EP